Advertisement

Organisation › Details
Exscientia (Group)
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches. Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development. Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi, Evotec, Roche and Celgene Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan. *
![]() |
Start | 2016-04-26 existent |
![]() |
Industry | drug discovery |
Industry 2 | small-molecule cancer drug | |
![]() |
Person | Hopkins, Andrew (Ex Scientia 201604 CEO) |
Person 2 | Taylor, Ben (Exscientia 202011– CFO before Aetion + Tyme Technologies + Goldman Sachs + Barclays) | |
![]() |
Region | Oxford, Oxfordshire |
Country | United Kingdom (GB) | |
Street | 36 St. Giles’ | |
City | OX1 3LD Oxford, Oxfordshire | |
Tel | +44-1865-818941 | |
Address record changed: 2021-04-03 | ||
Basic data | Employees | D: 101 to 500 (2021-09-01) |
Currency | GBP | |
Annual sales | 9,672,000 (revenue, consolidated (2020 2020-12-31) | |
Profit | -22,283,000 (2020-12-31) | |
Cash | 62,584,000 (2020-12-31) | |
* Document for �About Section�: Exscientia Ltd.. (3/22/19). "Press Release: Exscientia Continues Expansion with Establishment of a Subsidiary in Japan to Target the Pharmaceutical Market Across Asia". Oxford & Osaka. | ||
Record changed: 2021-12-31 |
Advertisement
![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
More documents for Exscientia (Group)
- [1] Exscientia plc. (1/7/22). "Press Release: Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines". Paris, Oxford & Boston, MA....
- [2] Exscientia plc. (10/5/21). "Press Release: Exscientia Announces Closing of $510.4 Million Aggregate Financing". Oxford....
- [3] Exscientia plc. (9/30/21). "Press Release: Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements". Oxford....
- [4] Exscientia Ltd.. (9/8/21). "Press Release: Exscientia Enters $70M Collaboration to Develop Anti-viral Therapeutics against Coronavirus and other Viruses with Pandemic Potential"....
- [5] Exscientia Ltd.. (8/18/21). "Press Release: Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate". Oxford....
- [6] Exscientia Ltd.. (8/4/21). "Press Release: Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline"....
- [7] Exscientia Ltd.. (7/21/21). "Press Release: Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture". Oxford & Shanghai....
- [8] Exscientia Ltd.. (7/8/21). "Press Release: Exscientia Accelerates COVID-19 Drug Discovery Using AI". Oxford....
- [9] Exscientia Ltd.. (6/24/21). "Press Release: EQRx and Exscientia Enter Strategic Drug Creation, Development and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines". Cambridge, MA & Oxford....
- [10] Exscientia Ltd.. (6/15/21). "Press Release: Exscientia Acquires Personalised Medicine AI Pioneer Allcyte"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top